![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Karachi (AFP) Aug 18, 2020
Pakistan regulators have approved final-phase testing of a Chinese-made vaccine against the coronavirus, officials said Tuesday, in the country's first ever clinical trial of its kind. According to Pakistan's National Institute of Health (NIH), regulators have approved the testing of a vaccine under development by CanSinoBio and the Beijing Institute of Biotechnology China. The medication is already undergoing Phase 3 trials -- or large-scale testing on humans -- in China, Russia, Chile and Argentina. Saudi Arabia will also take part, NIH said. "This will be the first ever Phase 3 clinical trial for any vaccine in Pakistan," the NIH said in a statement. Pakistan's inclusion in the trials would help it secure "preferential vaccine supply and pricing", it added. The trials will be conducted at several medical facilities across Pakistan, including the large Indus Hospital in Karachi. "Hopefully we will come out with the vaccine within three to four months," Abdul Bari, who heads the Indus Hospital, told AFP. The coronavirus has claimed more than 6,000 lives in Pakistan but cases have been dropping for several weeks.
![]() ![]() Global health emergencies: A rarely used call to action Geneva (AFP) Jan 22, 2020 The World Health Organisation (WHO) is holding emergency talks Thursday in Geneva to decide whether a deadly virus outbreak in China constitutes a "public health emergency of international concern". The designation is rare and only used for the gravest outbreaks which are considered "serious, sudden, unusual or unexpected". The classification would imply that the disease, which has killed nine people so far, risks spreading further internationally and requires an international response. The ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |